BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 16
• 17
• 18
• 19
• 20
• 23
• 24
• 25
• 26
• 27

• 

  Layoff Tracker

  Bayer’s BlueRock Lays Off 50 in Streamlining Effort

  Follow along as BioSpace tracks job cuts and restructuring initiatives throughout 2025.

  June 26, 2025

   · 

  148 min read

   · 

  BioSpace Editorial Staff
• 

  Government

  Trump’s CDC Pick Says Vaccines Are Safe, Promises To Keep Them Available

  Susan Monarez, already acting director of the CDC, said during her confirmation hearing that she sees no causal link between vaccines and autism.

  June 26, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Longevity Biotech Takes Root on Nasdaq With $180M SPAC Deal

  Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic mitochondria.

  June 26, 2025

   · 

  1 min read

   · 

  Annalee Armstrong
• 

  Mergers & acquisitions

  Lilly-Verve Proxy Filing Reveals Tumult After Departure of FDA’s Marks

  Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing than normal” given the regulatory turmoil it revealed.

  June 26, 2025

   · 

  4 min read

   · 

  Annalee Armstrong
• 

  Cardiovascular disease

  Novartis Makes Potential $750M+ Bet Per Cardiovascular Disease Target in Another Flagship Pact

  Flagship Pioneering’s ProFound Therapeutics will use its proprietary technology to mine the expanded proteome for novel cardiovascular therapeutics. Novartis has promised to pay up to $750 million per target, though it has not specified how many targets it will go after.

  June 26, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Policy

  Novavax Approval Process a Potential ‘Harbinger’ of Threat to FDA Integrity: Former Regulators

  Writing in JAMA, four former government officials warn that the Trump administration’s involvement in delaying the approval of Novavax’s COVID-19 vaccine could indicate a politicization of the drug approval processes that could ‘imperil public health.’

  June 26, 2025

   · 

  5 min read

   · 

  Dan Samorodnitsky
• 

  Job Trends

  Thanks, But No Thanks: Biopharmas Hiring Less International Talent

  Given today’s available local talent pool, biopharma companies are less likely to turn toward international job candidates, according to a talent acquisition expert. Findings from two recent BioSpace LinkedIn polls underscore the issue.

  June 26, 2025

   · 

  4 min read

   · 

  Angela Gabriel
• 

  Policy

  Former CBER Chief Marks Decries New FDA COVID-19 Framework

  Peter Marks, who headed the FDA’s Center for Biologics Evaluation and Research before being forced to resign in March, said the agency’s new risk-based COVID-19 vaccine framework contradicts the current administration’s push for transparency and gold-standard science.

  June 26, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Vaccines

  RFK Cuts U.S. Funding From Vaccine Alliance Gavi, Claims Group ‘Ignored the Science’

  Without providing further context, HHS Secretary Robert F. Kennedy Jr. says that Gavi needs to “start taking vaccine safety seriously” by considering “the best science available.”

  June 26, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts

  June 26, 2025

   · 

  3 min read